ClinicalTrials.gg
RecruitingNCT02355171PMTUpdated Nov 5, 2026

Personalize My Treatment (PMT) Registry

An observational study in Cancer, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 14 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Observational

How we know

Updated Nov 5, 2026Now RecruitingNow Active, not recruiting+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Study summary

The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 20,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sir Mortimer B. Davis - Jewish General Hospital is the lead sponsor of 62 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients with all solid tumor types.

Eligibility criteria

Age of majority in the province of recruitment.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
20,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research.

    Time frame: Longitudinal

07

Study locations

1 of 14 sites recruiting
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
    Suspended

    Not enrolling at this site.

  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
    Suspended

    Not enrolling at this site.

  • Centre Hospitalier Universitaire Dr-Georges-L.-Dumont
    Moncton, New Brunswick E1C 2Z3, Canada
    Suspended

    Not enrolling at this site.

  • The Moncton Hospital
    Moncton, New Brunswick E1C 6Z8, Canada
    Suspended

    Not enrolling at this site.

  • QE II Health Sciences Centre
    Halifax, Nova Scotia B3H 1V8, Canada
    Suspended

    Not enrolling at this site.

  • London Health Science Centre
    London, Ontario, Canada
    Suspended

    Not enrolling at this site.

  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
    Suspended

    Not enrolling at this site.

  • Odette Cancer Centre - Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
    Suspended

    Not enrolling at this site.

  • Centre hospitalier de l'Université de Montréal
    Montreal, Quebec H2X 0A9, Canada
    Suspended

    Not enrolling at this site.

  • Jewish General Hospital University Health Centre
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • MUHC McGill University Health Center
    Montreal, Quebec H4A 3J1, Canada
    Suspended

    Not enrolling at this site.

  • Centre hospitalier universitaire de Québec - Université Laval
    Québec, Quebec H3T 1Y6, Canada
    Suspended

    Not enrolling at this site.

  • Centre hospitalier universitaire de Sherbrooke
    Sherbrooke, Quebec J1G 2E8, Canada
    Suspended

    Not enrolling at this site.

  • CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional
    Trois-Rivières, Quebec G8Z 3R9, Canada
    Suspended

    Not enrolling at this site.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.

09

Timeline

2 registry updates since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Nov 2015, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2024 → Dec 2030, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2015
First posted
Feb 4, 2015
Start
Nov 2015
Primary completionEst.
Dec 2030was Dec 2024
CompletionEst.
Dec 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Active, not recruiting→Recruiting Reason for stopping removed
changed Oct 13, 2026 · changed Nov 5, 2026
Sites
1 site added, 1 site removed. 14 sites changed recruiting status (13 now suspended, 1 now recruiting)
Show 14 sites
  • Tom Baker Cancer Centre · Calgary, Canadano status→Suspended
  • Cross Cancer Institute · Edmonton, Canadano status→Suspended
  • Centre Hospitalier Universitaire Dr-Georges-L.-Dumont · Moncton, Canadano status→Suspended
  • The Moncton Hospital · Moncton, Canadano status→Suspended
  • QE II Health Sciences Centre · Halifax, Canadano status→Suspended
  • London Health Science Centre · London, Canadano status→Suspended
  • The Ottawa Hospital · Ottawa, Canadano status→Suspended
  • Odette Cancer Centre - Sunnybrook Hospital · Toronto, Canadano status→Suspended
  • Centre hospitalier de l'Université de Montréal · Montreal, Canadano status→Suspended
  • Jewish General Hospital University Health Centre · Montreal, Canadano status→Recruiting
  • MUHC McGill University Health Center · Montreal, Canadano status→Suspended
  • Centre hospitalier universitaire de Québec - Université Laval · Québec, Canadano status→Suspended
  • Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Canadano status→Suspended
  • CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional · Trois-Rivières, Canadano status→Suspended
Show site
  • Jewish General Hospital University Health Centre · Montreal, Canada
Show 1 removed
  • Jewish General Hospital · Montreal, Canada
across 2 updates, Oct 13, 2026 – Nov 5, 2026
Primary completion
Dec 13, 2024→Dec 2030
Oct 13, 2026
Study completion
Set to Dec 2030
Oct 13, 2026
Enrollment
10000→20000
Oct 13, 2026
Contact
Study contact now listed: added g•••@ssss.gouv.qc.ca · •••8222; added c•••@ladydavis.ca · •••8222. See the current contact
Nov 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Jewish General Hospital University Health Centre · Montreal, CanadaContact added c•••@ladydavis.ca · •••8222Contact added (no phone or email listed)
Nov 5, 2026
Sponsor
Exactis Innovation→Sir Mortimer B. Davis - Jewish General Hospital
Oct 13, 2026
Show all 2 updates
  1. Nov 5, 2026
    Active, not recruiting→Recruiting
    14 sites changed recruiting status (13 now suspended, 1 now recruiting)
    Show 14 sites
    • Tom Baker Cancer Centre · Calgary, Canadano status→Suspended
    • Cross Cancer Institute · Edmonton, Canadano status→Suspended
    • Centre Hospitalier Universitaire Dr-Georges-L.-Dumont · Moncton, Canadano status→Suspended
    • The Moncton Hospital · Moncton, Canadano status→Suspended
    • QE II Health Sciences Centre · Halifax, Canadano status→Suspended
    • London Health Science Centre · London, Canadano status→Suspended
    • The Ottawa Hospital · Ottawa, Canadano status→Suspended
    • Odette Cancer Centre - Sunnybrook Hospital · Toronto, Canadano status→Suspended
    • Centre hospitalier de l'Université de Montréal · Montreal, Canadano status→Suspended
    • Jewish General Hospital University Health Centre · Montreal, Canadano status→Recruiting
    • MUHC McGill University Health Center · Montreal, Canadano status→Suspended
    • Centre hospitalier universitaire de Québec - Université Laval · Québec, Canadano status→Suspended
    • Centre hospitalier universitaire de Sherbrooke · Sherbrooke, Canadano status→Suspended
    • CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional · Trois-Rivières, Canadano status→Suspended
    Contact Study contact now listed: added g•••@ssss.gouv.qc.ca · •••8222; added c•••@ladydavis.ca · •••8222. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Jewish General Hospital University Health Centre · Montreal, CanadaContact added c•••@ladydavis.ca · •••8222Contact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 13, 2026
    Suspended→Active, not recruiting
    Why stopped Reason for stopping removed
    1 site added, 1 site removed
    Show site
    • Jewish General Hospital University Health Centre · Montreal, Canada
    Show 1 removed
    • Jewish General Hospital · Montreal, Canada
    Primary completion Dec 13, 2024→Dec 2030
    Study completion Set to Dec 2030
    Enrollment 10000→20000
    Sponsor Exactis Innovation→Sir Mortimer B. Davis - Jewish General Hospital
    + 4 other changes: index terms, identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02355171
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Collaborators
Lady Davis Institute, McGill Centre for Translational Research in Cancer
Responsible party
Sponsor
First posted
Feb 4, 2015
Start date
Nov 2015
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Gerald Batist, MD
Contact
gerald.batist.med@ssss.gouv.qc.ca
514-340-8222 ext. 25418
Cyrla Hoffert, MSc
Contact
cyrla.hoffert@ladydavis.ca
514-340-8222 ext. 27992

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion